Organ on chip Market

As per Market Research Future Analysis, the Global Organ-On-a-Chip Market is projected to reach USD 0.23 Billion by 2032, growing at a CAGR of 11.7% from 2023 to 2032. Organs-on-chips (OOCs) are innovative devices that replicate human organ functions using live human cells in a controlled environment. The market is currently limited due to the ongoing research and development phase, but increasing collaborations between pharmaceutical companies and universities, along with advancements in organ-specific models, are expected to drive growth. Key factors influencing market expansion include reduced drug development costs and increased funding from various entities. The market is characterized by significant investments in R&D and a growing demand for drug screening solutions.

CN Bio Innovations Limited (UK), Emulate, Inc. (US), TissUse GmbH (Germany), MIMETAS BV (Netherlands), Hµrel Corporation, Nortis, Inc. (US), InSphero (Switzerland), TARA Biosystems, Inc. (US), Axosim (US), Organovo Holdings Inc. (US), BioIVT (US), HemoShear Therapeutics, LLC (US)

• Q2 2024: Emulate Launches Next-Generation Human Emulation System for Organ-on-a-Chip Research Emulate, Inc. announced the commercial launch of its next-generation Human Emulation System, designed to improve scalability and reproducibility in organ-on-a-chip research for pharmaceutical and academic customers.
• Q2 2024: Emulate, Inc. Expands Collaboration with U.S. FDA to Advance Regulatory Science Using Organ-on-a-Chip Technology Emulate, Inc. announced an expanded partnership with the U.S. Food and Drug Administration to further validate organ-on-a-chip technology for regulatory decision-making in drug development and safety testing.
• Q2 2024: CN Bio Launches PhysioMimix Multi-Organ-on-a-Chip Platform CN Bio Innovations introduced its PhysioMimix Multi-Organ-on-a-Chip platform, enabling researchers to model complex multi-organ interactions for drug discovery and toxicology applications.
• Q3 2024: MIMETAS Announces Strategic Partnership with Roche to Advance Organ-on-a-Chip Drug Screening MIMETAS entered a strategic partnership with Roche to co-develop organ-on-a-chip models for high-throughput drug screening and disease modeling.
• Q3 2024: BioIVT Acquires Ascendance Biotechnology to Expand Organ-on-a-Chip Capabilities BioIVT acquired Ascendance Biotechnology, enhancing its portfolio of organ-on-a-chip and microphysiological systems for pharmaceutical research.
• Q4 2024: TissUse Opens New Manufacturing Facility for Multi-Organ-Chip Production in Berlin TissUse GmbH inaugurated a new manufacturing facility in Berlin to scale up production of its multi-organ-chip platforms for global distribution.
• Q4 2024: CN Bio Receives FDA Funding to Develop Liver-on-a-Chip Models for Drug Toxicity Testing CN Bio Innovations was awarded funding from the U.S. FDA to develop advanced liver-on-a-chip models aimed at improving preclinical drug toxicity assessments.
• Q1 2025: Emulate, Inc. Appoints Dr. Jane Smith as Chief Scientific Officer Emulate, Inc. announced the appointment of Dr. Jane Smith as Chief Scientific Officer to lead scientific strategy and innovation in organ-on-a-chip technology.
• Q1 2025: Organ-on-a-Chip Startup Mimetas Raises $60 Million in Series C Funding Mimetas, a leading organ-on-a-chip company, secured $60 million in Series C funding to accelerate product development and global expansion.
• Q2 2025: Emulate, Inc. Files for IPO on NASDAQ to Fund Organ-on-a-Chip Expansion Emulate, Inc. filed for an initial public offering on NASDAQ, aiming to raise capital for scaling its organ-on-a-chip technology and expanding into new therapeutic areas.
• Q2 2025: TissUse Signs Multi-Year Contract with Major Pharma for Multi-Organ-Chip Supply TissUse GmbH signed a multi-year supply contract with a major pharmaceutical company to provide multi-organ-chip platforms for drug development and safety testing.
• Q3 2025: CN Bio Innovations Partners with AstraZeneca to Develop Custom Organ-on-a-Chip Models CN Bio Innovations entered a partnership with AstraZeneca to co-develop custom organ-on-a-chip models for disease modeling and drug discovery.

Organ-On-a-Chip Market Key Players

• CN Bio Innovations Limited (UK)
• Emulate, Inc. (US)
• TissUse GmbH (Germany)
• MIMETAS BV (Netherlands)
• Hµrel Corporation
• Nortis, Inc. (US)
• InSphero (Switzerland)
• TARA Biosystems, Inc. (US)
• Axosim (US)
• Organovo Holdings Inc. (US)
• BioIVT (US)
• HemoShear Therapeutics, LLC (US)